Aurinia Pharmaceuticals (AUPH) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 144.6% versus a gain of 36.7%. Over five years, DNTH leads with a -21.2% price change compared with -22.2% for AUPH. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $2.13 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | DNTH |
|---|---|---|
| Share price | $16.01 | $84.88 |
| Market cap | $2.13B | $4.75B |
| 1-day change | +2.04% | -0.61% |
| YTD return | +0.38% | +105.97% |
| 1-year return | +36.72% | +144.61% |
| 5-year return | -22.17% | -21.17% |
| P/E ratio (TTM) | 7.02 | — |
| Forward P/E | 15.01 | — |
| EPS (TTM) | $2.28 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.04M |
| Revenue growth (YoY) | — | -67.35% |
| Net income (latest FY) | — | $-162.34M |
| Operating margin | — | -8739.34% |
| Net margin | — | -7973.33% |
| 52-week high | $19.25 | $117.88 |
| 52-week low | $10.90 | $32.22 |
| Distance from 52-week high | -16.83% | -27.99% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +11.56% | +65.88% |
| Average volume | 1.01M | 825.33K |
| Shares outstanding | 133.05M | 55.93M |
| Employees | 128 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Dianthus Therapeutics is about 2.2 times larger than Aurinia Pharmaceuticals by market value ($4.75B vs $2.13B).
- DNTH has outperformed AUPH by 107.9 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
AUPH vs DNTH FAQ
Which is bigger, Aurinia Pharmaceuticals or Dianthus Therapeutics?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $2.13B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or DNTH?
DNTH returned +144.61% over the past 12 months, compared with +36.72% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Dianthus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.